Sign In
Buy CVS
$98.32
-0.84 (-0.85%)
At Close: Jun 18, 2026
DASH Feeds Bulls, UPST's Blowout Earnings, CVS Hits 4-Month High
10:30am, Wednesday, 12'th Feb 2025
DoorDash (DASH) managed a revenue beat and shared outlook that signaled bulls to buy. That company's rally didn't match Upstart's (UPST) 30% gain after it shared strong optimism on the quarter and its
CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
09:40am, Wednesday, 12'th Feb 2025
CVS tops earnings and revenue estimates in the fourth quarter of 2024 amid macroeconomic impacts in the Health Care Benefits arm.
CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates
08:41am, Wednesday, 12'th Feb 2025
CVS Health (CVS) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $2.12 per share a year ago.
CVS Health Q4 Earnings: Revenue And EPS Beat, Same-store Prescription Volume Up 5.9%, Upbeat FY25 Outlook And More
08:23am, Wednesday, 12'th Feb 2025
On Wednesday, CVS Health Corp CVS reported fourth-quarter sales of $97.71 billion, beating the consensus of $97.19 billion.
CVS's stock soars after a big profit beat, continued improvement in PBM business
08:07am, Wednesday, 12'th Feb 2025
CVS's stock soared toward a three-month high after its quarterly profit beat expectations by the widest margin in more than four years.
CVS Health beats quarterly profit estimates on lower medical costs
06:37am, Wednesday, 12'th Feb 2025
CVS Health reported a smaller-than-expected drop in fourth-quarter profit on Wednesday as the pace of medical cost increases slowed at the healthcare conglomerate and revenues jumped in its pharmacy b
CVS results top estimates even as high medical costs drag down insurance unit
06:32am, Wednesday, 12'th Feb 2025
CVS Health reported fourth-quarter revenue and profit that topped estimates, even as its troubled insurance business saw higher medical costs. The company also issued a full-year 2025 adjusted profi
CVS Health 2024 Profits Eclipse $4.6 Billion Despite Rising Costs
06:30am, Wednesday, 12'th Feb 2025
CVS Health reported $4.6 billion in 2024 profits including $1.6 billion in the fourth quarter as the company worked to overcome rising medical expenses from patients in its health insurance business.
CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2024 RESULTS
06:30am, Wednesday, 12'th Feb 2025
Fourth Quarter Highlights Total revenues increased to $97.7 billion, up 4.2% compared to prior year GAAP diluted EPS of $1.30 and Adjusted EPS of $1.19 Full-Year Highlights Total revenues increased to
CVS Stock Approaches Q4 Earnings With Resistance In Sight
02:16pm, Tuesday, 11'th Feb 2025
CVS Health Corp CVS will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects 94 cents in EPS and $97.20 billion in revenues as the company reports before market hours.
What's a Fair Price for CVS Stock?
09:57am, Tuesday, 11'th Feb 2025
CVS (CVS 1.23%) is struggling to stay relevant amid rising costs and declining customer visits.
CVS Health's turnaround efforts in focus amid record-high medical costs
09:03am, Tuesday, 11'th Feb 2025
CVS Health investors will closely examine this week turnaround initiatives spearheaded by new CEO David Joyner and their impact on cost pressures in its health insurance business.
Dividend Roundup: Why CVS Health Is Still Better Than Walgreens
01:22pm, Monday, 10'th Feb 2025
Investors drawn to WBA and CVS must feel disappointed. WBA's recent dividend suspension and CVS's dividend freeze reflect financial headwinds and operational challenges. I won't consider either as a b
CVS Health (CVS) Is Considered a Good Investment by Brokers: Is That True?
10:36am, Monday, 10'th Feb 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Billionaire Sold META and Is Buying This Stock That Could Soar 53% According to a Wall Street Expert
09:27am, Saturday, 08'th Feb 2025
It's more than worthwhile to keep up with what the big money is doing of late. While riding on the coattails of an investing legend may not lead to outperformance in any given year, it can be a subtle
